Transfection Reagent & Equipment Market Worth $1.09Bn By 2022

January 2016 | Report Format: Electronic (PDF)

The global transfection reagent & equipment market is expected to reach USD 1,086.02 million by 2022, according to a new report by Grand View Research, Inc. This anticipated growth in demand can be attributed to growing need for protein production, biopharmaceutical development, and vaccine research and development; all of which rely heavily on cytological R&D and transfection.

Larger market entities are also involved in efforts to expand their market presence in the Asia Pacific region and tap the high potential for growth available. Expected growth of genomic and proteomic research is also a strong factor which will positively impact the growth in demand for transfection.

Out of both the broad segments of products available, transfection equipment accounted for a larger share of the market in 2014 and owing to their inherently more expensive nature than reagents are expected to maintain this dominant position over the forecast period.

The market space for transfection has an abundant number of methods to achieve the aforementioned. However, these vary significantly in usage rates and implementation complexities. Electroporation and liposomal transfection combine to account for over 30% of the market owing to high associated advantages.

Growing applications of transfection techniques poise the segments in a strong position and estimated valuation clocks usage of transfection in gene expression at over USD 130 million and for protein production at over USD 110 million for the year 2014.

North America was observed to be responsible for the largest share of revenue in 2014 which amounted to a little over USD 240 million. The United States houses the headquarters of operations for a number of market leaders and a number of established research and development. This provides a strong platform for development, manufacture & distribution various vaccines, and biopharmaceuticals which fuels market growth.

However, it is Asia Pacific region which is anticipated to witness significant growth over the forecast period in various segments owing to considerable growth of cytological research, development of biosimilar drugs and high potential of growth in these relatively untapped regional segments.

Asia Pacific is expected to grow at a significant rate over the forecast period in terms of increasing production and development of vaccines, drugs, and new biologics. Supportive government initiatives pertaining to increasing investments by manufacturers and governments in biopharmaceutical manufacturing and high untapped market opportunities are the important factors accounting for the expected growth of market in this region over the forecast period.

Promega, Roche and Thermo Fisher owned Life Technologies accounted for the largest of revenue in 2014 and are involved in new product development for expansion of their portfolios over the forecast period. Acquisition of smaller players is also expected over the forecast period by larger companies